Saturday 17 October 2026
Export SPRO’s income statement to Excel — free account
Spero Therapeutics, Inc.
SPRO Healthcare Biotechnology
Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 95.6%, EPS fell 433.3% and free cash flow grew 69.7%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
1.10
0.03
−2.65%
Follow SPRO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.53 | 0.00 | 15.53 |
Piotroski F-Score |
— | — | 3 | 3 | 2 | 4 | 4 | 4 | 2 | 5 |
P/S ratio |
0.00 | 15.87 | 24.81 | 9.63 | 46.52 | 27.09 | 1.22 | 0.77 | 1.16 | 1.95 |
Altman Z-Score |
— | 0.31 | 2.96 | (0.33) | 8.97 | (0.04) | (3.65) | (0.81) | (6.43) | 1.04 |
Altman Z″-Score (non-manufacturers) |
(23.71) | 9.98 | 9.21 | (3.40) | 2.45 | (4.00) | (6.62) | (1.33) | (13.81) | (8.90) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(0.37) | (2.47) | (7.28) | (10.06) | (26.49) | (18.09) | 1.47 | (4.58) | (2.38) | (15.63) |
Beneish M-Score |
— | 2.44 | (0.47) | 1.95 | (2.40) | (3.17) | (3.03) | 21.97 | (4.29) | (1.00) |
P/B ratio |
0.00 | 0.37 | 0.85 | 2.34 | 3.29 | 5.60 | 0.86 | 0.75 | 1.21 | 2.21 |
Price to Tangible BV |
0.00 | 0.37 | 0.85 | 2.34 | 3.29 | 5.60 | 0.86 | 0.75 | 1.21 | 2.21 |
EV/Sales |
0.00 | (28.24) | (4.29) | 5.11 | 32.92 | 19.08 | (0.82) | 0.04 | 0.06 | 1.35 |
EV/EBITDA |
0.61 | 1.35 | 0.40 | 0.00 | 0.00 | 0.00 | 1.06 | 0.17 | 0.00 | 14.30 |
EV/Operating CF |
0.61 | 1.43 | 0.43 | (1.85) | (3.58) | (5.41) | 5.65 | (0.11) | (0.12) | (7.15) |
EV/FCF |
0.61 | 1.39 | 0.40 | (1.84) | (3.57) | (5.41) | 5.63 | (0.11) | (0.12) | (7.13) |
Quick Ratio |
1.54 | 11.06 | 9.48 | 3.40 | 9.28 | 7.98 | 5.09 | 3.42 | 2.15 | 7.40 |
Current Ratio |
1.72 | 11.29 | 10.08 | 3.58 | 9.70 | 8.46 | 5.25 | 3.53 | 2.19 | 7.59 |
Net Debt/EBITDA |
0.31 | 2.11 | 2.72 | 1.31 | 1.62 | 1.68 | 2.64 | (3.49) | 0.72 | (6.38) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.05 | 0.04 | 0.04 | 0.15 | 0.07 | 0.11 | 0.36 | 0.68 | 0.33 | 0.74 |
Operating CF/Net income |
0.97 | 0.85 | 0.95 | 0.82 | 1.09 | 0.72 | 0.17 | (1.45) | 0.34 | (1.47) |
Capex/Depreciation |
(2.97) | (0.07) | (5.96) | (0.42) | (0.21) | 0.06 | 0.00 | 0.00 | 0.00 | — |
Interest Coverage |
— | (137.72) | (37.42) | (47.60) | (197.29) | (45.35) | (16.20) | — | — | — |
| (169.30%) | (258.18%) | (41.49%) | (63.99%) | (76.31%) | (81.48%) | (56.53%) | 24.95% | (89.62%) | 16.31% | |
| (434.62%) | (85.96%) | (37.45%) | (51.83%) | (60.74%) | (55.32%) | (31.37%) | 14.85% | (46.81%) | 9.55% | |
ROIC |
0.00% | 0.00% | (6,493.63%) | 0.00% | (963.10%) | 0.00% | 0.00% | 43.93% | 0.00% | 21.04% |
Return on Tangible Assets |
(463.71%) | (54.19%) | (36.29%) | (85.78%) | (62.33%) | (64.01%) | (50.29%) | 24.25% | (117.81%) | 14.67% |
Average Days of Receivables |
331.22 | 542.80 | 119.46 | 171.89 | 241.61 | 52.80 | 7.39 | 178.30 | 399.23 | 138.71 |
Research and Development Expense of Revenue |
7,860.60% | 1,660.89% | 854.39% | 362.46% | 718.15% | 353.45% | 88.94% | 49.57% | 201.67% | 57.58% |
Selling, General and Administrative Expense of Revenue |
2,156.12% | 547.75% | 324.94% | 85.90% | 229.80% | 228.42% | 68.18% | 24.62% | 49.41% | 31.70% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
53.73% | 72.11% | 69.31% | 20.81% | 52.39% | 51.65% | 17.05% | 7.64% | 16.24% | 6.47% |
Graham Net Nets |
5.11 | 2.66 | 1.13 | 0.37 | 0.27 | 0.15 | 0.99 | 0.70 | 0.77 | 0.44 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.43 | 0.00 | 1.89 |
Earnings Yield |
(951.57%) | (710.00%) | (42.76%) | (34.30%) | (18.62%) | (18.05%) | (95.40%) | 28.29% | (123.30%) | 6.44% |
Free Cash Flow Yield |
(922.37%) | (128.00%) | (43.03%) | (28.81%) | (19.82%) | (13.02%) | (11.88%) | (41.24%) | (42.19%) | (9.70%) |
Revenue per Share |
1.07 | 0.77 | 0.25 | 1.00 | 0.42 | 0.59 | 1.42 | 1.97 | 0.89 | 1.19 |
Operating CF per Share |
(92.76) | (15.12) | (2.48) | (2.75) | (3.84) | (2.08) | (0.21) | (0.63) | (0.43) | (0.23) |
Capex per Share |
(2.66) | (0.01) | (0.15) | (0.02) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(95.42) | (15.13) | (2.63) | (2.77) | (3.84) | (2.08) | (0.21) | (0.63) | (0.43) | (0.23) |
Cash per Share |
33.04 | 33.74 | 7.21 | 4.52 | 5.67 | 4.74 | 2.90 | 1.45 | 0.98 | 0.72 |
Shareholders Equity per Share |
20.37 | 32.84 | 7.24 | 4.11 | 5.90 | 2.86 | 2.02 | 2.03 | 0.85 | 1.05 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
20.37 | 32.84 | 7.24 | 4.11 | 5.90 | 2.86 | 2.02 | 2.03 | 0.85 | 1.05 |
Free Cash Flow |
(29.79) | (39.14) | (42.06) | (50.33) | (86.03) | (64.31) | (7.73) | (32.99) | (23.44) | (12.62) |
Working Capital |
4.95 | 83.90 | 111.90 | 68.75 | 124.80 | 139.20 | 91.92 | 94.06 | 58.20 | 58.42 |
Capital Expenditures |
(0.83) | (0.03) | (2.44) | (0.31) | (0.16) | 0.04 | — | — | — | — |
Net Current Asset Value |
4.46 | 83.54 | 111.07 | 63.89 | 117.73 | 75.09 | 64.70 | 55.71 | 42.86 | 57.39 |
EV/EBIT |
0.60 | 1.34 | 0.40 | 0.00 | 0.00 | 0.00 | 1.04 | 0.18 | 0.00 | 14.30 |
Capex to Sales |
2.48 | 0.01 | 0.61 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.73 | 0.00 | 20.67 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.19 | 0.31 | 0.14 | 0.33 | 0.46 | 0.63 | 2.36 | 183.50 | 0.00 | — |
Cash ROIC |
(178.63%) | (22.72%) | (18.18%) | (32.14%) | (33.22%) | (27.40%) | (4.18%) | (18.01%) | (23.68%) | (12.71%) |
Accounts Receivable Turnover |
0.21 | 1.22 | 1.87 | 3.69 | 1.27 | 4.14 | 28.73 | 4.01 | 0.93 | 1.72 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
1.62 | 1.62 | 2.12 | 4.92 | 7.36 | 4.41 | 1.86 | 25.89 | 51.59 | 38.93 |
Average Payables |
2.30 | 2.30 | 3.54 | 3.88 | 2.65 | 1.13 | 0.86 | 1.00 | 4.34 | 4.00 |
Average Assets |
6.89 | 53.63 | 111.24 | 117.55 | 129.78 | 162.26 | 147.94 | 153.60 | 146.47 | 89.73 |
Average Common Equity |
17.68 | 17.85 | 100.41 | 95.21 | 103.31 | 110.16 | 82.11 | 91.41 | 76.51 | 52.57 |
Columns are period end dates